KEROS THERAPEUTICS IN

Keros Therapeutics to Present at Upcoming Healthcare Conferences

07 ноя 2023 08:00:00 Источник Nasdaq GlobeNewswire

Keros Therapeutics Reports Recent Business Highlights and Third Quarter 2023 Financial Results

06 ноя 2023 08:00:01 Источник Nasdaq GlobeNewswire

Keros Therapeutics to Present at the 65th American Society of Hematology Annual Meeting and Exposition

02 ноя 2023 09:00:00 Источник Nasdaq GlobeNewswire

Keros Therapeutics Presents Preclinical Data from its KER-065 Program at the 28th International Annual Congress of the World Muscle Society

04 окт 2023 08:00:00 Источник Nasdaq GlobeNewswire

Keros Therapeutics to Present at Upcoming Healthcare Conferences

05 сен 2023 08:00:00 Источник Nasdaq GlobeNewswire

Keros Therapeutics Reports Recent Business Highlights and Second Quarter 2023 Financial Results

07 авг 2023 08:00:00 Источник Nasdaq GlobeNewswire

Corrected: Keros Therapeutics to Host Conference Call and Webcast to Provide an Overview of TROPOS, the KER-012 Phase 2 Clinical Trial in Patients with Pulmonary Arterial Hypertension

27 июл 2023 16:01:00 Источник Nasdaq GlobeNewswire

Keros Therapeutics Announces Update to Participation at the Goldman Sachs 44th Annual Global Healthcare Conference

12 июн 2023 08:00:00 Источник Nasdaq GlobeNewswire

Keros Therapeutics Presents Clinical Trial and Preclinical Study Results from its KER-050 Program and Preclinical Data from its ALK2 Inhibitor Program at the 28th Annual Congress of the European Hematology Association

09 июн 2023 06:00:00 Источник Nasdaq GlobeNewswire

Keros Therapeutics to Present at Goldman Sach’s 44th Annual Global Healthcare Conference

07 июн 2023 08:00:00 Источник Nasdaq GlobeNewswire

Keros Therapeutics Presents Preclinical and Clinical Data from its KER-012 Program at the American Thoracic Society International Conference

22 май 2023 09:00:00 Источник Nasdaq GlobeNewswire

Keros Therapeutics to Present at the 28th Annual Congress of the European Hematology Association

11 май 2023 16:01:01 Источник Nasdaq GlobeNewswire

Keros Therapeutics Reports Recent Business Highlights and First Quarter 2023 Financial Results

04 май 2023 16:01:00 Источник Nasdaq GlobeNewswire

Keros Therapeutics Appoints Alpna Seth, Ph.D., to its Board of Directors

19 апр 2023 08:00:00 Источник Nasdaq GlobeNewswire

Keros Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2022 Financial Results

03 мар 2023 16:01:00 Источник Nasdaq GlobeNewswire

Keros Therapeutics to Present at Cowen’s 43rd Annual Health Care Conference

01 мар 2023 08:00:02 Источник Nasdaq GlobeNewswire

Keros Therapeutics to Present at the SVB Securities Global Biopharma Conference

07 фев 2023 08:00:01 Источник Nasdaq GlobeNewswire

Keros Therapeutics Presents Clinical Data from its KER-050 and KER-047 Programs and Preclinical Data from its KER-050 and ALK2 Inhibitor Programs at the 64th American Society of Hematology Annual Meeting and Exposition

12 дек 2022 10:00:00 Источник Nasdaq GlobeNewswire

Keros Therapeutics to Present at Upcoming Healthcare Conferences

22 ноя 2022 08:00:01 Источник Nasdaq GlobeNewswire

Keros Therapeutics Presents Preclinical Data from its KER-012 Program at the American Heart Association 2022 Scientific Sessions

07 ноя 2022 16:01:00 Источник Nasdaq GlobeNewswire